Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 27, 2015 12:27 PM ET

Healthcare Equipment and Supplies

Company Overview of TheraDiag SA

Company Overview

TheraDiag SA engages in the development, industrialization, and marketing of diagnosis kits in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay; immunofluorescence tests to screen and identify the auto-antibodies; ELISA tests for performing various tests on the same plate; Chorus systems, compact multi-parametric analyzers; and immunoblot tests, which allow simultaneous detection of antibodies. The company also provides genetic tests comprising AmplideX products line for the diagnosis of the Fragile X syndrome; xTAG Gastrointestinal Pathogens Panel kits for identifying various gas...

4-6 Bd de Beaubourg

Actipole 25

CS 90136 Croissy Beaubourg

cedex 2

Marne-la-Vallée,  77435

France

Founded in 1986

64.4 Employees

Phone:

33 1 64 62 10 12

Fax:

33 1 64 62 09 12

Key Executives for TheraDiag SA

Chief Executive Officer and Director
Age: 57
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2013.

TheraDiag SA Key Developments

Theradiag and Hospira Sign Partnership Agreement

Theradiag announced it has entered into a partnership agreement with Hospira regarding the supply of LISA-TRACKER CE-marked infliximab monitoring kit. Theradiag will supply and will also ensure installation and training in laboratories and provide information and follow-up with clinicians on behalf of Hospira. LISA TRACKER infliximab kits have been validated for use with Inflectra®.

TheraDiag SA Enters into Exclusive Distribution Agreement with Somagen Diagnostics

TheraDiag SA announced that it has entered into an exclusive distribution agreement with Somagen Diagnostics Inc., for the launch in Canada of its biotherapy monitoring range LISA TRACKER. Canadian Health Authorities have positioned themselves in favor of biotherapy monitoring2. This positive recommendation should benefit sales of LISA TRACKER in the country. LISA TRACKER kits are currently registered for sale in the European Union, North Africa, the Middle-East, India3 and Australia. They were registered in Canada in 2014.

Theradiag Announces New Marne-La-Valle Facility

Theradiag announced that it has moved into its new Marne-La-Valle facility, in the Paris area. The company's new location offers over 3,200 square meters of R&D and production laboratories, and office space. This represents a 60% gain in floor space with no significant increase in rental costs. Two thirds of the increase in space is allocated to R&D and production facilities, which will allow the Company to increase the volume of production and automation of its proprietary products.

Similar Private Companies By Industry

Company Name Region
Biocode Hycel France S.A. Europe
Shamir France S.A.R.L. Europe
Lunettes de Protection Essilor S.A. Europe
AMS R&D SAS Europe
SOLUSCOPE SAS Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TheraDiag SA, please visit www.theradiag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.